Resultados da busca - Bruno Vergès
- Mostrando 1 - 20 resultados de 52
- Ir para a próxima página
-
1
Lipid modification in type 2 diabetes: the role of LDL and HDL por Bruno Vergès
Publicado em 2009Revisão -
2
Pathophysiology of diabetic dyslipidaemia: where are we? por Bruno Vergès
Publicado em 2015Revisão -
3
Lipid disorders in type 1 diabetes por Bruno Vergès
Publicado em 2009Revisão -
4
Dyslipidemia in Type 1 Diabetes: A Masked Danger por Bruno Vergès
Publicado em 2020Revisão -
5
-
6
Intestinal lipid absorption and transport in type 2 diabetes por Bruno Vergès
Publicado em 2022Revisão -
7
-
8
-
9
-
10
-
11
CB1 Antagonism Exerts Specific Molecular Effects on Visceral and Subcutaneous Fat and Reverses Liver Steatosis in Diet-Induced Obese Mice por Tony Jourdan, Louiza Djaouti, Laurent Demizieux, Joseph Gresti, Bruno Vergès, Pascal Degrace
Publicado em 2010Artigo -
12
-
13
HDL particles from type 1 diabetic patients are unable to reverse the inhibitory effect of oxidised LDL on endothelium-dependent vasorelaxation por L. Perségol, Matthieu Foissac, Laurent Lagrost, Anne Athias, Philippe Gambert, Bruno Vergès, Laurence Duvillard
Publicado em 2007Artigo -
14
-
15
Protection against stroke with glucagon-like peptide-1 receptor agonists: a comprehensive review of potential mechanisms por Bruno Vergès, Victor Aboyans, Denis Angoulvant, Pierre Boutouyrie, Bertrand Cariou, Fabien Hyafil, Kamel Mohammedi, Pierre Amarenco
Publicado em 2022Revisão -
16
Management of pasireotide-induced hyperglycemia in patients with acromegaly: An experts’ consensus statement por Sylvère Störmann, Sebastian M. Meyhöfer, Jan B. Groener, Johanna Faust, Katharina Schilbach, Jochen Seufert, Bruno Vergès
Publicado em 2024Artigo -
17
Glycated Albumin With Loss of Fatty Acid Binding Capacity Contributes to Enhanced Arachidonate Oxygenation and Platelet Hyperactivity: Relevance in Patients With Type 2 Diabetes por Denis Blache, Emmanuel Bourdon, Pauline Salloignon, Géraldine Lucchi, Patrick Ducoroy, Jean‐Michel Petit, Bruno Vergès, Laurent Lagrost
Publicado em 2014Artigo -
18
Pituitary Disease in MEN Type 1 (MEN1): Data from the France-Belgium MEN1 Multicenter Study por Bruno Vergès, Françoise Boureille, Pierre Goudet, Arnaud Murat, Albert Beckers, Geneviève Sassolas, P Cougard, Béatrice Chambe, Corinne Montvernay, Alain Calender
Publicado em 2002Artigo -
19
Glycation of Apolipoprotein C1 Impairs Its CETP Inhibitory Property: Pathophysiological Relevance in Patients With Type 1 and Type 2 Diabetes por Benjamin Bouillet, Thomas Gautier, Denis Blache, Jean-Paul Paı̈s de Barros, Laurence Duvillard, Jean‐Michel Petit, Laurent Lagrost, Bruno Vergès
Publicado em 2014Artigo -
20
Effect of liraglutide therapy on liver fat content in patients with inadequately controlled type 2 diabetes. The Lira-NAFLD study por Jean‐Michel Petit, Jean–Pierre Cercueil, Romaric Loffroy, Damien Denimal, Benjamin Bouillet, C. Fourmont, Olivier Chevallier, Laurence Duvillard, Bruno Vergès
Publicado em 2016Artigo
Ferramentas de busca:
Assuntos relacionados
Medicine
Internal medicine
Endocrinology
Diabetes mellitus
Type 2 diabetes
Cholesterol
Biology
Chemistry
Disease
Lipoprotein
Obesity
Insulin
Insulin resistance
Biochemistry
Gastroenterology
Lipid metabolism
Pathology
Apolipoprotein B
Fatty liver
Metabolic syndrome
Triglyceride
Very low-density lipoprotein
Body mass index
Environmental health
Steatosis
Type 1 diabetes
Adiponectin
Glycemic
Hormone
Liraglutide